v3.26.1
Segment Information - Schedule of Significant Expenses (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
May 31, 2026
May 31, 2025
May 31, 2026
May 31, 2025
Segment Reporting [Line Items]        
Total research and development expenses $ 87,653 $ 78,096 $ 171,789 $ 147,759
Reportable Segment        
Segment Reporting [Line Items]        
Total research and development expenses 87,653 78,096 171,789 147,759
Bexobrutideg (NX-5948) | Reportable Segment        
Segment Reporting [Line Items]        
Total research and development expenses 28,192 18,558 52,166 34,278
Zelebrudomide (NX-2127) | Reportable Segment        
Segment Reporting [Line Items]        
Total research and development expenses 1,167 1,559 3,073 2,665
NX-1607 | Reportable Segment        
Segment Reporting [Line Items]        
Total research and development expenses 1,738 2,332 2,926 4,292
Internal research and development expenses | Reportable Segment        
Segment Reporting [Line Items]        
Total research and development expenses $ 56,556 $ 55,647 $ 113,624 $ 106,524